175 related articles for article (PubMed ID: 25266877)
21. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
22. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
[TBL] [Abstract][Full Text] [Related]
23. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.
Lu Z; Wang J; Zheng Y; Yang S; Liu M; Chen X; Wang C; Hou G
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26725440
[TBL] [Abstract][Full Text] [Related]
24. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
25. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
26. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
28. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
29. Methylxanthine derivatives promote autophagy in gastric cancer cells targeting PTEN.
Liu H; Song J; Zhou Y; Cao L; Gong Y; Wei Y; Yang H; Tang L
Anticancer Drugs; 2019 Apr; 30(4):347-355. PubMed ID: 30875347
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
31. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells.
Zhuo Z; Yu H
Oncotarget; 2017 Apr; 8(17):28042-28051. PubMed ID: 28427207
[TBL] [Abstract][Full Text] [Related]
32. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
Zhao LJ; Liu N; Li XP; Wang JL; Wei LH
Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558
[TBL] [Abstract][Full Text] [Related]
33. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
[TBL] [Abstract][Full Text] [Related]
35. Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells.
Tsubamoto H; Inoue K; Sakata K; Ueda T; Takeyama R; Shibahara H; Sonoda T
Anticancer Res; 2017 Feb; 37(2):515-519. PubMed ID: 28179296
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
[TBL] [Abstract][Full Text] [Related]
37. Exenatide inhibits the growth of endometrial cancer Ishikawa xenografts in nude mice.
Zhang Y; Xu F; Liang H; Cai M; Wen X; Li X; Weng J
Oncol Rep; 2016 Mar; 35(3):1340-8. PubMed ID: 26648451
[TBL] [Abstract][Full Text] [Related]
38. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.
Yunokawa M; Koizumi F; Kitamura Y; Katanasaka Y; Okamoto N; Kodaira M; Yonemori K; Shimizu C; Ando M; Masutomi K; Yoshida T; Fujiwara Y; Tamura K
Cancer Sci; 2012 Sep; 103(9):1665-71. PubMed ID: 22703543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]